Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Landos Biopharma, Inc. (LABP)
|
Add to portfolio |
|
|
|
| Price: |
$4.97
| | Metrics |
| OS: |
3.12
|
M
| |
-53
|
% ROE
|
| Market cap: |
$15.5
|
M
| |
1075
|
% ROIC
|
|
Net cash:
|
$44
|
M
| |
$14.13
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$15.3
|
M
| |
-1.9
|
x EV/EBITDA
|
|
EBIT
|
$15.3
|
M
| |
-1.9
|
x EV/EBIT
|
| EPS |
($1.05)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.0 | 18.0 | 0.0 | 11.8 | 6.8 |
| Revenue growth | -100.0% | | -100.0% | 73.6% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 13.3 | 7.9 |
| Gross profit | 0.0 | 18.0 | 0.0 | -1.5 | -1.1 |
| Gross margin | | 100.0% | | -12.5% | -16.7% |
| Selling, general and administrative | 40.6 | 56.8 | 30.7 | | |
| General and administrative | | | | 1.5 | 1.1 |
| EBIT | 0.0 | -38.8 | -30.7 | -13.3 | -7.9 |
| EBIT margin | | -215.6% | | -112.5% | -116.7% |
| Pre-tax income | -39.3 | -38.4 | -30.1 | -13.5 | -6.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -39.3 | -38.4 | -30.1 | -13.5 | -6.0 |
| Net margin | | -213.5% | | -114.0% | -88.8% |
| |
| Diluted EPS | ($0.98) | ($1.02) | ($2.47) | ($1.18) | ($0.59) |
| Shares outstanding (diluted) | 40.3 | 37.6 | 12.2 | 11.4 | 10.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|